安斯泰来Astellas Pharma（4503）2025财年第三季度财务业绩报告「TSX」（英文版）（20页）.pdf

1、February 4,2026 Contact:Communications and Investor Relations,Astellas Pharma Inc.TEL+81-3-3244-3201 Financial Results of Astellas for the First Nine Months of FY2025 Japan,February 4,2026 Astellas Pharma Inc.(TSE:4503,President and CEO:Naoki Okamura,“the Company”)today announced the financial resul

2、ts for the first nine months(April 1,2025 December 31,2025)of the fiscal year 2025 ending March 31,2026(FY2025).Consolidated financial results for the first nine months of FY2025(core basis)(Millions of yen)First nine months of FY2024 First nine months of FY2025 Change(%)Revenue 1,453,029 1,601,320+

3、148,291(+10.2%)Core operating profit 297,543 442,063+144,520(+48.6%)Core profit 223,060 331,635+108,575(+48.7%)Cautionary Notes In this material,statements made with respect to current plans,estimates,strategies and beliefs and other statements that are not historical facts are forward-looking state

4、ments about the future performance of Astellas.These statements are based on managements current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties.A number of factors could cause actual results to differ materially fro

5、m those discussed in the forward-looking statements.Such factors include,but are not limited to:(i)changes in general economic conditions and in laws and regulations,relating to pharmaceutical markets,(ii)currency exchange rate fluctuations,(iii)delays in new product launches,(iv)the inability of As

6、tellas to market existing and new products effectively,(v)the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets,and(vi)infringements of Astellas intellectual property rights by third parties.Information about pharmaceut